NCT02640222View on ClinicalTrials.gov

APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study

CompletedOBSERVATIONAL
Enrollment

321,501

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2019

Conditions
Anticoagulation
Interventions
DRUG

VKA

DRUG

Apixaban

DRUG

dabigatran

DRUG

rivaroxaban

Trial Locations (1)

Unknown

Rueil-Malmaison

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY